Semaglutide vs. Tirzepatide: What's the Difference?
If you're researching medications for weight management, you've probably encountered two names again and again: semaglutide and tirzepatide.
Both are injectable medications associated with significant weight loss in clinical trials. Both affect GLP-1 pathways. Both are available under well-known brand names.
But semaglutide and tirzepatide aren't the same medication.
The biggest difference is how they work: semaglutide activates GLP-1 receptors, while tirzepatide activates both GLP-1 and GIP receptors. And in a major head-to-head clinical trial published in 2025, tirzepatide produced greater average weight loss than semaglutide among adults with obesity who did not have diabetes.
That doesn't automatically make one medication "better" for every person.
Here's a plain-English look at semaglutide vs. tirzepatide, including how they work, their brand names, weight-loss results, side effects, and why tracking your individual experience can matter just as much as comparing averages.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist.
GLP-1—short for glucagon-like peptide-1—is a hormone your body naturally produces. Among its functions, GLP-1 is involved in blood glucose regulation, digestion, appetite, and food intake.
Semaglutide is designed to activate GLP-1 receptors for much longer than your body's naturally produced GLP-1 remains active.
You may know semaglutide by two particularly prominent brand names:
Wegovy contains semaglutide and is FDA-approved for weight management in eligible patients, along with other approved indications.
Ozempic also contains semaglutide, but its FDA-approved indications relate to type 2 diabetes and associated cardiovascular and kidney risks in certain patients. The fact that Ozempic and Wegovy contain the same active ingredient does not make the two products interchangeable.
Semaglutide is also available in oral formulations for certain indications.
What Is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist.
That's the most important biological distinction when comparing tirzepatide vs. semaglutide.
Instead of activating only GLP-1 receptors, tirzepatide activates receptors for two hormones:
GLP-1: glucagon-like peptide-1
GIP: glucose-dependent insulinotropic polypeptide
Both are involved in metabolic processes following food intake.
Tirzepatide's effects include reducing calorie intake through effects on appetite. It also affects insulin and glucagon secretion in a glucose-dependent manner.
The two brand names you're most likely to encounter are Zepbound and Mounjaro.
Zepbound is FDA-approved for chronic weight management in eligible adults, among other approved uses.
The Biggest Difference: One Hormone Pathway vs. Two
Here's an easy way to remember the difference:
Semaglutide → GLP-1
Tirzepatide → GIP + GLP-1
That's an oversimplification of some complicated biology, but it's a useful starting point.
Both medications can affect appetite and food intake, but tirzepatide's additional activity at the GIP receptor distinguishes it from semaglutide.
This is also why describing tirzepatide simply as another "GLP-1 agonist" doesn't tell the whole story. It's more accurately described as a dual GIP/GLP-1 receptor agonist.
Tirzepatide vs. Semaglutide for Weight Loss: What Does the Research Show?
This is probably the biggest question for people searching for semaglutide vs. tirzepatide:
Which produces more weight loss?
For years, comparisons were complicated because results came from separate clinical trials with different participants and study designs.
Then researchers compared the medications directly.
The SURMOUNT-5 trial
A phase 3b randomized trial published in The New England Journal of Medicine in 2025 compared tirzepatide and semaglutide in 751 adults with obesity but without type 2 diabetes.
Participants received the maximum tolerated dose of either tirzepatide or semaglutide for 72 weeks.
At week 72, average body-weight change was:
Tirzepatide: −20.2%
Semaglutide: −13.7%
Participants receiving tirzepatide also experienced a greater average reduction in waist circumference.
That's important evidence because the medications were compared within the same randomized trial rather than across unrelated studies.
But there's an equally important point:
Clinical-trial averages aren't personal predictions
A result such as "20.2% average weight loss" does not mean someone starting tirzepatide should expect to lose exactly 20.2% of their body weight.
Some participants lose more.
Some lose less.
Some discontinue treatment.
And your results can be influenced by numerous individual factors.
The trial also compared particular maximum tolerated doses under a specific research protocol. Since medication approvals and available doses can change over time, current treatment options should always be discussed with a healthcare professional. For example, the FDA approved an additional higher-dose Wegovy option in March 2026, after the SURMOUNT-5 comparison had been conducted.
So the study gives us valuable comparative evidence—but not a guarantee of what will happen to you.
Why Your Own Progress Matters More Than Someone Else's Percentage
Reading clinical studies can be useful.
Comparing yourself with their average participant every week usually isn't.
Your weight-loss journey is your own data set.
Suppose your scale hasn't moved much for two weeks.
That alone might feel discouraging.
But your journal might show that during those same two weeks:
your waist measurement changed;
you completed more workouts;
your food noise decreased;
you became more consistent with meal planning;
your clothes started fitting differently;
you maintained habits that used to be difficult; or
your appetite and eating patterns changed.
That's a much richer picture than a single number.
Whether you're using semaglutide, tirzepatide, or another medication as part of a clinician-guided weight-management plan, the Semaglutide Weight Loss Tracker helps you document 26 weeks of weight, medication, symptoms, food noise, meals, workouts, habits, measurements, goals, and reflections. Get your copy and follow your own progress instead of comparing your journey with someone else's.
Semaglutide vs. Tirzepatide Side Effects
Semaglutide and tirzepatide can both cause side effects, and gastrointestinal effects are common with this type of medication.
In the SURMOUNT-5 head-to-head trial, the most commonly reported adverse events in both groups were gastrointestinal. Most were mild to moderate and occurred primarily during dose escalation.
Depending on the specific medication, common side effects can include symptoms such as:
nausea;
diarrhea;
vomiting;
constipation; and
abdominal discomfort or pain.
Both medications also have warnings and potentially serious risks that go beyond these common symptoms.
That's why tracking side effects can be useful—but tracking should never replace medical care.
A symptom tracker can help you remember what happened and when so you can provide your healthcare professional with a clearer history.
If you experience severe, persistent, unusual, or concerning symptoms, contact your healthcare professional rather than simply recording them and waiting.
Why Keep a Medication Log?
When your treatment unfolds over months, remembering exactly what happened several weeks ago can become surprisingly difficult.
A medication log gives you a simple record.
Depending on your prescribed treatment, you might record:
date;
medication;
prescribed dose;
how the medication was taken;
injection site when applicable; and
notes about your experience.
This can be particularly useful as prescribed doses change over time.
But a medication tracker has an important limitation:
It records your treatment. It doesn't determine your treatment.
Your journal shouldn't tell you when to increase a dose, decrease a dose, skip a dose, or change medications. Those decisions should follow the prescribing information and guidance from your healthcare professional.
What About Food Noise?
One of the more interesting parts of a GLP-1 weight loss journey can be noticing changes that aren't easily captured on a scale.
"Food noise" is an informal term people use to describe frequent or persistent thoughts, urges, or mental preoccupation surrounding food.
It's not a formal medical measurement.
But your subjective experience can still be worth recording.
For example, you might rate your food noise from week to week using the same simple scale.
Over time, you may begin to see patterns.
Maybe your rating changes as treatment progresses.
Maybe certain weeks feel different from others.
Maybe your experience changes even before you see a major change on the scale.
Writing those observations down gives you something your weight alone cannot provide: context.
Semaglutide vs. Tirzepatide: Which Is Better?
There isn't a universal answer.
If "better" means which medication produced greater average weight loss in the 2025 SURMOUNT-5 head-to-head trial, the answer was tirzepatide. Participants taking tirzepatide lost an average of 20.2% of baseline body weight compared with 13.7% among those receiving semaglutide at 72 weeks.
But that's not the same as saying tirzepatide is the best medication for every individual.
Choosing a medication can involve much more than average weight loss, including:
your health history;
why the medication is being prescribed;
contraindications and warnings;
side effects;
other medications you take;
how you respond to treatment;
access and coverage; and
your healthcare professional's assessment.
The most effective medication on paper isn't automatically the most appropriate medication for a particular person.
That's a decision to make with a qualified healthcare professional who knows your medical history.
Don't Turn Your Weight Loss Journey Into a Race
With dramatic before-and-after stories everywhere online, it's easy to start measuring your success against someone else's.
"They lost 15 pounds already."
"I'm only losing this much."
"Someone online lost twice as much as I did."
That can turn a health journey into a race you're constantly afraid of losing.
Instead, look at your own trend.
Week 1 compared with Week 8.
Month 1 compared with Month 4.
Your habits then compared with your habits now.
Your measurements.
Your strength.
Your consistency.
Your relationship with food.
Your food noise.
Your energy.
Your non-scale victories.
Your experience deserves to be measured against your own starting point.
Tracking Can Help You See the Bigger Picture
Imagine reaching six months into your journey and being able to look back at more than a graph of your weight.
You could see when your habits started becoming consistent.
You could see changes in your measurements.
You could remember milestones you'd forgotten.
You could identify weeks when certain symptoms occurred.
You could compare your experience of food noise from your first month with your sixth.
And you could read what you wrote during difficult weeks and recognize just how much has changed since then.
That's the value of keeping a weight loss journal.
Not predicting what the medication will do.
Not diagnosing symptoms.
Not trying to micromanage every fluctuation.
Simply creating a record that helps you pay attention to your own experience.
Your progress deserves more than a number on the scale. The Semaglutide Weight Loss Tracker is a guided six-month journal for people navigating semaglutide, tirzepatide, and other GLP-1-based weight-loss journeys, with dedicated space for medication, symptoms, food noise, weight, measurements, meals, workouts, habits, goals, and weekly reflection. Get your copy and start building a record of what your progress actually looks like.
Semaglutide vs. Tirzepatide: The Bottom Line
If you're trying to remember the major differences, start here:
Semaglutide is a GLP-1 receptor agonist.
Tirzepatide is a dual GIP/GLP-1 receptor agonist.
For weight management, semaglutide is available as Wegovy and tirzepatide as Zepbound.
Both medications can affect appetite and food intake, and both can produce substantial weight loss in eligible patients.
In the 2025 SURMOUNT-5 head-to-head trial involving adults with obesity without diabetes, tirzepatide produced greater average weight loss and waist-circumference reduction than semaglutide at 72 weeks.
But averages tell you what happened across a study population.
They don't tell you exactly what will happen to you.
That's why your healthcare professional is the right person to help you evaluate treatment options—and why, once you've begun your own journey, tracking your individual progress can tell you something a clinical-trial average never can.
It tells you your story.
Medical disclaimer: This article is for general educational and informational purposes only and does not provide medical advice, diagnosis, dosing instructions, or treatment recommendations. Semaglutide and tirzepatide are prescription medications with contraindications, warnings, potential side effects, and drug interactions. Talk with a qualified healthcare professional about whether a medication is appropriate for you and how it should be used.
